Loading...
•
Jun 30, 2022
Atara Q2 2022 Earnings Report
Reported financial results for the second quarter 2022 and updated the corporate strategy.
Key Takeaways
Atara Biotherapeutics reported a net income of $18.5 million, or $0.18 per share, for the second quarter 2022, compared to a net loss of $83.8 million, or $0.91 per share, for the same period in 2021. The company's cash, cash equivalents, and short-term investments totaled $331.3 million as of June 30, 2022. Atara plans to focus on R&D activities, prioritizing key pipeline assets and reducing cash burn.
Atara to focus on R&D activities prioritizing upcoming milestones for key pipeline assets
ATA188 Phase 2 EMBOLD Study interim analysis completed with target enrollment achieved; primary endpoint data read out planned for October 2023
FDA recommended pathway to potential tab-cel BLA filing without need for new clinical trial; European Commission approval on track for Q4 2022
ATA3219 on track for Q4 2022 IND submission
Forward Guidance
Atara believes that its cash and investments as of June 30, 2022, together with the expected reductions in operating cash burn, will be sufficient to fund the Company’s planned operations into the first quarter of 2024
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...